Eurosurveillance最新文献_第6页

Increase in tuberculosis notification rates among newly arriving male Ukrainian refugees to Norway, 2022 to 2024. 2022年至2024年新抵达挪威的乌克兰男性难民中结核病通报率的增加。

IF 7.8 2区医学

Eurosurveillance Pub Date : 2025-08-01 DOI: 10.2807/1560-7917.ES.2025.30.34.2500633

Karine Nordstrand, Jacob Dag Berild

引用次数: 0

Doxycycline post-exposure prophylaxis (doxyPEP): balancing promise and prudence in the prevention of sexually transmitted infections. 多西环素暴露后预防（doxyPEP）：在预防性传播感染中平衡承诺与谨慎。

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.26.2500454

Fiona Lyons, Adam Shanley

引用次数: 0

Exploring all-cause mortality surveillance during the Iberian Peninsula power outage, Spain, 28 April 2025. 探讨2025年4月28日西班牙伊比利亚半岛停电期间的全因死亡率监测。

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.26.2500405

David García-García, Inmaculada León-Gómez, Lucía Pérez-Marín, Diana Gómez-Barroso

引用次数: 0

Detection of West Nile virus via retrospective mosquito arbovirus surveillance, United Kingdom, 2025. 通过蚊虫虫媒病毒回顾性监测检测西尼罗病毒，英国，2025。

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.28.2500401

Robert C Bruce, Anthony J Abbott, Ben P Jones, Bathsheba L Gardner, Estela Gonzalez, Andra-Maria Ionescu, Madhujot Jagdev, Ava Jenkins, Mariana Santos, Katharina Seilern-Macpherson, Hugh J Hanmer, Robert A Robinson, Alexander Gc Vaux, Nicholas Johnson, Andrew A Cunningham, Becki Lawson, Jolyon M Medlock, Arran J Folly

引用次数: 0

Author's correction for Euro Surveill. 2025;30(25). 作者对欧洲监测的更正。2025;30（25）。

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.28.250717c

引用次数: 0

National representative seroprevalence of viral hepatitis B, C, and D seromarkers in Ukraine, 2021. 2021年乌克兰乙型、丙型和丁型病毒性肝炎血清标志物的全国代表性血清阳性率

IF 7.8 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.29.2500015

Ludmila Kasatkina, Vladyslav Fedorchenko, Iryna Sidorova, Lidia Gomenyuk, Oleksandra Yakovets, Michael Brandl, Iryna Ivanchuk, Sandra Dudareva, Olena Nesterova

{"title":"National representative seroprevalence of viral hepatitis B, C, and D seromarkers in Ukraine, 2021.","authors":"Ludmila Kasatkina, Vladyslav Fedorchenko, Iryna Sidorova, Lidia Gomenyuk, Oleksandra Yakovets, Michael Brandl, Iryna Ivanchuk, Sandra Dudareva, Olena Nesterova","doi":"10.2807/1560-7917.ES.2025.30.29.2500015","DOIUrl":"10.2807/1560-7917.ES.2025.30.29.2500015","url":null,"abstract":"BACKGROUNDAligned with World Health Organization (WHO) goals, Ukraine aims to eliminate viral hepatitis. While some data on viral hepatitis B and C prevalence exist among key populations, nationwide prevalence in the general population has never been assessed.AIMTo assess the prevalence of viral hepatitis B, C, and D seromarkers in Ukraine in 2021 to plan and monitor elimination measures.METHODSBlood samples available from a cross-sectional household-based SARS-CoV-2 serosurvey conducted in 2021 were tested for hepatitis C virus (HCV) antibodies, total antibodies against hepatitis B virus (HBV) core antigen (HBc), hepatitis B surface antigen (HBsAg) and hepatitis D virus (HDV) antibodies. We calculated crude and weighted proportions for anti-HCV, anti-HBc and HBsAg positivity. To account for differences in sex, age group and urbanisation level, we applied post-stratification weights using inverse probability weighting based on the distribution of the Ukrainian population. We calculated proportions positive for anti-HDV among HBsAg-positive cases and weighted regional estimates for HBV and HCV seromarkers.RESULTSWeighted prevalence of anti-HCV was 3.3% (95% CI: 2.8-4.0), anti-HBc 11.6% (95% CI: 10.8-12.5) and HBsAg 0.9% (95% CI: 0.7-1.2). Among HBsAg-positive individuals, 7.5% (95% СI: 3.0-17.9) were anti-HDV positive. We found higher prevalence of HBV and HCV seromarkers among men and in southern Ukraine.CONCLUSIONHBsAg prevalence and considerably high anti-HBc and anti-HCV prevalence indicate substantial lifetime exposure. This reinforces the necessity of sustained prevention such as HBV vaccination of newborns and groups at increased risk, regular hepatitis B and C screening, early treatment, and raising awareness to reduce ongoing transmission.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 29","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023. 2019 - 2023年西班牙马德里高危移民人群活动性丙型肝炎感染流行及危险因素分析

IF 7.8 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.29.2500150

Pablo Ryan, Jorge Valencia, Felipe Pérez-García, Marta Quero-Delgado, Guillermo Cuevas, Samuel Manzano, Samuel Estévez, Isidoro Martínez, Daniel Sepúlveda-Crespo, Salvador Resino

{"title":"Prevalence and risk factors of active hepatitis C infection among at-risk migrant populations in Madrid, Spain, 2019 to 2023.","authors":"Pablo Ryan, Jorge Valencia, Felipe Pérez-García, Marta Quero-Delgado, Guillermo Cuevas, Samuel Manzano, Samuel Estévez, Isidoro Martínez, Daniel Sepúlveda-Crespo, Salvador Resino","doi":"10.2807/1560-7917.ES.2025.30.29.2500150","DOIUrl":"10.2807/1560-7917.ES.2025.30.29.2500150","url":null,"abstract":"BACKGROUNDHepatitis C virus (HCV) microelimination among at-risk migrants supports global elimination goals.AIMTo evaluate risk factors, prevalence and trends of active HCV infection among at-risk migrants screened for HCV in Madrid from 2019-23.METHODSAt-risk migrants (born outside Spain, living in country < 10 years regardless of legal status), were screened for HCV via mobile units with rapid antibody testing, and confirmed by RNA testing. Recruitment of this convenience sample focused on migrant centres, shelters, harm reduction centres and social service sites. Primary outcome was active HCV prevalence. Risk factors analysed included origin, alcohol use, no stable income, drug use and sexual behaviour. Data were analysed using general linear models with negative binomial distribution and p values adjusted for multiple comparisons (q values).RESULTSAmong 2,288 migrants, 6.5% (149/2,288) had anti-HCV antibodies, 47.0% (70/149) of whom tested positive for HCV-RNA; 81.4% (57/70) began antiviral therapy. Overall prevalence of active HCV infection was 3.1% (70/2,288). Injection drug use (non-active vs never used (aIRR: 7.3; 95% CI: 2.7-12.7) and active (aIRR: 14.7; 95% CI: 6.7-32.1)), European origin (vs non-European; aIRR: 5.8; 95% CI: 2.7-12.7) and alcohol misuse (vs no misuse; aIRR: 1.8; 95% CI: 1.1-2.9) were main risk factors. Prevalence showed no significant change during 2019-23 in the overall population and across risk groups.CONCLUSIONAt-risk migrants screened in Madrid had a high prevalence of active HCV infection. This is higher than reported estimates for the general Spanish population and supports the need to enhance targeted HCV prevention, screening and treatment strategies among migrant populations.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 29","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023. 2023年世卫组织欧洲区域早期采用6个月左氧氟沙星作为耐利福平结核病预防治疗方案的情况

IF 7.8 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.30.2500210

Irina Felker, Alexandra Solovyeva, Ana Ciobanu, Araksya Hovhannesyan, Dennis Falzon, Andrei Dadu

{"title":"Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023.","authors":"Irina Felker, Alexandra Solovyeva, Ana Ciobanu, Araksya Hovhannesyan, Dennis Falzon, Andrei Dadu","doi":"10.2807/1560-7917.ES.2025.30.30.2500210","DOIUrl":"10.2807/1560-7917.ES.2025.30.30.2500210","url":null,"abstract":"Tuberculosis (TB) preventive treatment (TPT) is crucial for preventing infection with Mycobacterium tuberculosis from progressing to TB disease, especially among people in high-risk groups. The expansion of novel TPT regimens for drug-susceptible TB is a notable advancement in TB care. However, managing contacts of drug-resistant TB patients remains a major challenge, particularly in Eastern Europe and Central Asia. In 2020, the World Health Organization (WHO) recommended TPT for high-risk household contacts of multidrug-resistant (MDR) or rifampicin-resistant (RR) TB patients; this was further reinforced in 2024 with a recommendation of a 6-month levofloxacin (6-Lfx) regimen. This Perspective discusses the early adoption of 6-Lfx for MDR/RR-TPT in the WHO European Region. In 2023, 38 of 53 WHO European Region countries reported on 6-Lfx use, with only eight confirming its use for MDR-TB contact persons. Accelerating the adoption of the 6-Lfx regimen and other evidence-backed TPT regimens is crucial for achieving TB elimination in the WHO European Region. Addressing challenges such as slow uptake of the recommendations, low awareness in affected communities and resource shortages are essential for success.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 30","pages":""},"PeriodicalIF":7.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12315515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Concurrent Cryptosporidium parvum outbreaks: molecular characterisation supporting epidemiological investigations leads to identification of different implicated food items, Sweden, 2019. 并发小隐孢子虫暴发：支持流行病学调查的分子特征导致识别不同的受影响食品，瑞典，2019年。

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.26.2400643

Ioana Bujila, Marie Jansson-Mörk, Joanna Nederby-Öhd, Anette Hansen, Mats Lindblad, Karolina Fischerstöm, Matilda Bragd, Ingela Hall, Nilla Lindroos, Caroline Rönnberg, Moa Rehn, Jessica Beser

{"title":"Concurrent Cryptosporidium parvum outbreaks: molecular characterisation supporting epidemiological investigations leads to identification of different implicated food items, Sweden, 2019.","authors":"Ioana Bujila, Marie Jansson-Mörk, Joanna Nederby-Öhd, Anette Hansen, Mats Lindblad, Karolina Fischerstöm, Matilda Bragd, Ingela Hall, Nilla Lindroos, Caroline Rönnberg, Moa Rehn, Jessica Beser","doi":"10.2807/1560-7917.ES.2025.30.26.2400643","DOIUrl":"10.2807/1560-7917.ES.2025.30.26.2400643","url":null,"abstract":"In Sweden, an increase in the number of notified cases of cryptosporidiosis was observed 1 October-31 December 2019 (462 domestic cases). Although a single national outbreak was initially suspected, molecular and epidemiological analyses revealed two concurrent national outbreaks and three local outbreaks. Cryptosporidium parvum subtype IIdA22G1c and IIdA24G1 were identified as the cause of the national outbreaks and subtype IIdA20G1e and IIdA21G1 as the cause of the local outbreaks. A case-case study comparing exposures in IIdA22G1c to IIdA24G1 revealed that cases with subtype IIdA22G1c (n = 48) were associated with consumption of a fresh fruit-and-vegetable juice (adjusted odds ratio (aOR) = 17; 95% confidence interval (CI): 1.8-169; p = 0.002). In the local outbreaks with subtype IIdA20G1e and IIdA21G1, cohort studies suggested that cases were associated with consumption of salads. Several coinciding outbreaks with different C. parvum subtypes explained the increase of cryptosporidiosis, and molecular typing was crucial in guiding relevant cross-disciplinary collaboration.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 26","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cross-border outbreak of Yersinia enterocolitica bioserotype 2/O:9 infections associated with consumption of French unpasteurised soft goat's milk cheese, 2024. 2024年与食用法国未经巴氏消毒的软羊奶奶酪有关的肠结肠炎耶尔森菌生物血清型2/O:9感染跨境暴发

IF 9.9 2区医学

Eurosurveillance Pub Date : 2025-07-01 DOI: 10.2807/1560-7917.ES.2025.30.26.2500002

Cyril Savin, Nathalie Fredriksen, Clémentine Calba, Lorraine Puzin, Arnaud Felten, Stéphane Larréché, Anthony Roche, Martine Denis, Anne-Sophie Le Guern, Fanny Chereau

{"title":"Cross-border outbreak of Yersinia enterocolitica bioserotype 2/O:9 infections associated with consumption of French unpasteurised soft goat's milk cheese, 2024.","authors":"Cyril Savin, Nathalie Fredriksen, Clémentine Calba, Lorraine Puzin, Arnaud Felten, Stéphane Larréché, Anthony Roche, Martine Denis, Anne-Sophie Le Guern, Fanny Chereau","doi":"10.2807/1560-7917.ES.2025.30.26.2500002","DOIUrl":"10.2807/1560-7917.ES.2025.30.26.2500002","url":null,"abstract":"In March 2024, the French genomic surveillance of enteric yersiniosis identified a cluster of lineage 2/3-9b Yersinia enterocolitica isolates, corresponding to bioserotype 2/O:9. An outbreak investigation was conducted to identify the source and implement control measures. A total of 175 confirmed cases were identified in France with sampling dates between 27 January and 23 August. Case interviews and trace-back investigations identified unpasteurised soft goat's milk cheese from one manufacturer in France as the probable source of the outbreak. Yersinia enterocolitica belonging to the same cluster as the case isolates was isolated from 23 samples from the manufacturer and a goat farm supplying milk to the dairy. Cheeses from the manufacturer were recalled in France. A Rapid Alert System for Food and Feed (RASFF) notification was issued, allowing the identification of cheese distribution from the manufacturer to 29 countries. An Epipulse alert led to the identification of seven additional cases in Belgium, Luxembourg and Norway, illustrating the value of international warning systems. This outbreak demonstrates risks with consumption of unpasteurised cheese and emphasises the need of rigorous good hygiene practices on dairy farms and dairies, especially when milk is processed without pasteurisation.","PeriodicalId":12161,"journal":{"name":"Eurosurveillance","volume":"30 26","pages":""},"PeriodicalIF":9.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0